The authors reply

New England Journal of Medicine

Volumn 368, Issue 15, 2013, Pages 1457-

  Van Den Berg, H Marijke ^a   Gouw, Samantha C ^b   Van Der Bom, Johanna G ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

CELL STRAIN BHK; HEMOPHILIA; HUMAN; LETTER; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY;

EID: 84875954404     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1301995     Document Type: Letter

References (2)

1. Jiang R, Monroe T, McRogers R, Larson PJ. Manufacturing challenges in the commercial production of recombinant coagulation factor VIII. Haemophilia 2002;8:Suppl 2:1-5. (Pubitemid 34498620)
2. Pipe SW. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost 2005;3:1692-701. (Pubitemid 41716555)